Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α2b and ribavirin:: An open-label series
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α2b and ribavirin:: An open-label series
复制标题
DOI：
10.1097/01.tp.0000100481.14514.bb
复制
发表时间：
2004-01-27
期刊：
影响因子：
6.2
通讯作者：
Vargas, HE
中科院分区：
文献类型：
--
作者：
Rodriguez-Luna, H;Khatib, A;Vargas, HE
背景丙型肝炎病毒（HCV）复发是原位肝移植（奥尔特）后的普遍现象。我们的目的是评估聚乙二醇干扰素（PEG-IFN）和利巴韦林（RIB）治疗肝移植术后HCV复发的有效性和安全性。对37例肝奥尔特后复发的HCV患者进行了筛查并开始治疗。19名患者已完成治疗。PEG-IFN以每周0.5 μ g/kg的剂量开始，并逐渐增加至每周1.5 μ g/kg的最大剂量。RIB的起始剂量为400 mg/天，并逐渐增加至最大剂量1000 mg/天（如耐受）。在逆转录聚合酶链反应检测不到HCV复制后继续治疗1年，如果在48周时没有病毒学清除，则停止治疗。12例患者（63%）完成了联合治疗方案。7例（37%）患者停止治疗。7例患者（37%）在治疗结束时检测不到病毒载量。其中，5名患者（26%）在停止治疗后6个月持续病毒应答。5例患者（26%）无病毒学应答。无应答者的坏死性炎症评分从5.22降至2.89（P=0.05），而无应答者为6.8降至2.6（P
Background. Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) is universal. We aimed to evaluate the efficacy and safety of pegylated interferon (PEG-IFN) and ribavirin (RIB) in the treatment of post-OLT HCV recurrence.Methods. Thirty-seven patients with recurrent HCV after OLT were screened and began treatment. Nineteen patients have completed therapy. PEG-IFN was started at a dose of 0.5 mug/kg per week and titrated toward a maximum dose of 1.5 mu/kg per week. RIB was started at a dose of 400 mg per day and titrated toward a maximum of 1000 mg per day, as tolerated. Therapy continued for 1 year after HCV replication was undetectable by reverse transcriptase-polymerase chain reaction and was discontinued if there was no virologic clearance at 48 weeks.Results. Twelve patients (63%) completed the combination regimen. Therapy was discontinued in seven (37%) patients. Seven patients (37%) had undetectable viral load at the end of treatment. Of those, five patients (26%) had sustained viral response 6 months after discontinuation of therapy. Five patients (26%) had no virologic response. Necro-inflammatory score declined from 5.22 to 2.89 (P=0.05) in nonresponders versus 6.8 to 2.6 (P